Sinopharm Says Test Subjects for World’s First COVID-19 Inactivated Vaccine All Produced High Concentrations of Antibodies


Chinese state-owned pharmaceutical giant Sinopharm has hailed the success of trials of its COVID-19 inactivated vaccine, pointing to the production of high-concentrations of antibodies in all test subjects.

Sinopharm announced on 16 June that stage 1 and stage 2 clinical trials of the world’s first COVID-19 inactivated vaccine developed by its  Wuhan In­sti­tute of Bi­o­log­i­cal Prod­ucts (武汉生物制品研究所) had proven the product’s safety, with no severe adverse reactions.

According to Sinopharm all 1,120 vaccine recipients aged from 18 to 59 had produced high concentrations of antibodies irrespective of initial dosage.

Sinopharm said that on 12 April the vaccine became the world’s first COVID-19 inactivated vaccine to obtain approval for clinical testing, with stage 1 and stage II tests held concurrently in the Hubei province capital of Wuhan and Wuzhi county in Henan province.

On 29 May Sinopharm sub­sidiary China Biotech­nol­ogy Co., Ltd. (中国生物技术股份有限公司) an­nounced that Sinopharm chair Liu Jingzhen (刘敬桢) was one of 180 early vol­un­teers who have re­ceived doses of a Novel Coro­n­avirus in­ac­ti­vated vac­cine. 

According to Sinopharm the next step will be to undertake overseas cooperation for stage 3 clinical trials of the vaccine, with several companies and research institutions already expressing interest.

Sinopharm’s Bei­jing Bi­o­log­i­cal Prepa­ra­tions In­sti­tute has already com­pleted con­struc­tion of a vac­cine pro­duc­tion plant in Bei­jing, which will sat­isfy biosafety level (BSL) 3 re­quire­ments and have an an­nual ca­pac­ity of 100 – 120 mil­lion doses. 

Its Wuhan In­sti­tute of Bi­o­log­i­cal Prod­ucts has also com­menced work on a vac­cine pro­duc­tion fa­cil­ity which is sched­uled for com­ple­tion prior to the end of June, and will bring an­nual pro­duc­tion to at least 200 mil­lion doses. 

Related stories

China Says That Its COVID-19 Vac­cine Will Be a “Pub­lic Good”

Five COVID-19 Vac­cines in China in Stage II Clin­i­cal Tri­als, “Emer­gency” So­lu­tion Ready by End of 2020: Zhong Nan­shan

Sinopharm Chair­man Says COVID-19 Vac­cine Has Proven Suc­cess­ful af­ter Serv­ing as Test Sub­ject Him­self

Coro­n­avirus Vac­cine Trial in Wuhan Has Proven Suc­cess­ful Ac­cord­ing to Peer-Re­viewed Lancet Re­port